SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.20-5.5%Nov 12 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JMarcus who wrote (8004)3/12/2003 2:14:07 AM
From: JMarcus   of 52153
 
I just listened to EPIX CEO Michael Webb's presentation at the Feb. 26th session of the BIO CEO & Investor Conference.
He says that EPIX has development deals with the three major MRI machine manufacturers: GE, Philips and Siemens. EPIX is the only small cap player in the MRI imagent field, and these manufacturers have been eager to deal with EPIX. According to Webb, the amount of up-front pre-commercial-release collaboration with these manufacturers has been unique. They are going so far as to install an MS 325 button on the new scanning machines so that they will be pre-set for running the optimal MS 325 exam. He also says that there are APC codes already in place for MRI angiograms, because the drawbacks (both in terms of cost and risk) to X-ray angiograms are such that reimbursers are eager to endorse the switch-over to MRI angiography once the NDA is approved. The first NDA will cover about 8000 vascular procedures. Operating profit is about $100 per vial, of which EPIX will receive $40-50 under its 50/50 profit sharing arrangement with Schering. Webb projects $150M in product revenue on 3M procedures per year. He says that would generate an EPS in the $4-6 range. The long-range goal, of course, is to grow the vascular imaging market. I think the potential is there because of the great value this tool provides to the diagnostician. EPIX also has a pipeline of promising new imagents for other MRI procedures (e.g., blood clots and breast cancer tumors).

Marc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News